Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
0 hedge funds and large institutions have $0 invested in Yield10 Bioscience, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 19 closing their positions.
13.28% less ownership
Funds ownership: 13.28% → 0% (-13%)
100% less funds holding
Funds holding: 19 → 0 (-19)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $612K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 19
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$352K |
| 2 |
Cannell & Spears
New York
|
-$94.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$23.7K |
| 5 |
Marex Group
London,
|
-$19.5K |
YTEN Hedge Fund Activity: Q2 2024 in Review
0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q2 2024, worth a combined $0 — down 100% from $612K a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of YTEN and 0 opened new positions — a net loss of 19 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $352K sold.
- 0 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q2 2024, down from 19 in Q1 2024.
- Funds reported $0 of Yield10 Bioscience, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q2 2024 and 19 closed out, a net change of -19 holders.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q2 2024 was Armistice Capital, an estimated $352K sold.
Based on aggregated 13F filings for Q2 2024.